AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
70.91
+0.47 (0.67%)
Dec 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 70.69 - 71.21
52 week 58.29 - 82.68
Open 70.70
Vol / Avg. 439,679.00/1.72M
Mkt cap 89.29B
P/E 87.27
Div/yield 0.90/3.95
EPS 0.81
Shares 1.26B
Beta 0.58
Inst. own 7%
Feb 5, 2015
Full Year 2014 AstraZeneca PLC Earnings Release - 3:00AM EST - Add to calendar
Nov 18, 2014
AstraZeneca PLC Investor Day - Webcast
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Call - Webcast
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 3.87% 10.00%
Operating margin 8.27% 14.44%
EBITD margin - 31.92%
Return on average assets 1.77% 4.70%
Return on average equity 4.80% 10.89%
Employees 51,500 -
CDP Score - 85 B

Address

2 Kingdom Street, Paddington
LONDON, W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Bio & Compensation  - Reuters
Paul Hudson Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Briggs Morrison Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters
David Smith Executive Vice President - Operations and Information Services
Bio & Compensation  - Reuters